VEXAS syndrome has an unmet need for therapeutic interventions. Even if few data exist
regarding the treatment of this newly described syndrome, different options can be proposed …

Establishing a diagnosis of aplastic anemia (AA) can be challenging, but it is absolutely
critical to appropriate management, especially differentiating between acquired and …

Background In patients undergoing allogeneic hematopoietic stem-cell transplantation
(HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality.
It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or …

目的: 探讨单倍型造血干细胞移植(haplo-HSCT) 治疗重型再生障碍性贫血(SAA) 的疗效. 方法:
回顾性分析2012 年9 月—2019 年11 月接受HID-HSCT 的120 例儿童和成人SAA …

PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited
among persons of non-European ancestry if human leukocyte antigen (HLA) matching is …

Background Relapsed severe aplastic anaemia is a marrow failure disorder with high
morbidity and mortality. It is often treated with bone marrow transplantation at relapse post …

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …